(0.81%) 5 059.26 points
(0.77%) 38 195 points
(1.36%) 15 817 points
(0.22%) $79.17
(5.02%) $2.03
(0.29%) $2 317.60
(0.69%) $26.93
(1.18%) $966.15
(-0.05%) $0.933
(-0.38%) $10.99
(-0.04%) $0.798
(-1.40%) $91.96
4 days till quarter result
(amc 2024-05-06)
Expected move: +/- 3.58%
@ $401.93
Išleistas: 1 geg. 2024 @ 22:53
Grąža: -0.10%
Ankstesnis signalas: geg. 1 - 16:35
Ankstesnis signalas:
Grąža: 1.47 %
Live Chart Being Loaded With Signals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation...
Stats | |
---|---|
Šios dienos apimtis | 538 613 |
Vidutinė apimtis | 1.12M |
Rinkos kapitalizacija | 103.72B |
EPS | $0 ( 2024-02-05 ) |
Kita pelno data | ( $4.10 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 28.93 |
ATR14 | $5.55 (1.38%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Sachs Bruce I | Buy | 109 | Deferred Stock Units |
2024-04-01 | Ambrose Kristen | Sell | 225 | Common Stock |
2024-04-02 | Ambrose Kristen | Sell | 240 | Common Stock |
2024-02-23 | Wagner Charles F Jr | Sell | 3 309 | Common Stock |
2024-02-23 | Tatsis Ourania | Sell | 3 309 | Common Stock |
INSIDER POWER |
---|
11.73 |
Last 100 transactions |
Buy: 259 544 | Sell: 201 703 |
Tūris Koreliacija
Vertex Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Vertex Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Vertex Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $9.84B |
Bruto pelnas: | $8.58B (87.17 %) |
EPS: | $14.05 |
FY | 2023 |
Pajamos: | $9.84B |
Bruto pelnas: | $8.58B (87.17 %) |
EPS: | $14.05 |
FY | 2022 |
Pajamos: | $8.93B |
Bruto pelnas: | $7.85B (87.90 %) |
EPS: | $12.97 |
FY | 2021 |
Pajamos: | $7.57B |
Bruto pelnas: | $6.67B (88.06 %) |
EPS: | $9.09 |
Financial Reports:
No articles found.
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.